StreetInsider.com News Articles

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

The analyst comments: “We downgrade to Hold, given the absence of key value-crystallising catalysts during 2H, despite the long-term valuation remaining attractive. Belief in amylin petrelintide will take time to build, whilst GLP-1/Glu survodutide's valuation hinges on 2H27E events, including success in the liver disease Phase III studies and initial launch metrics. Reduced time to key catalysts and greater visibility into ZEAL's early-stage research could make us more positive.

Following recent disappointing Phase III survodutide results at ADA, we

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

Following recent disappointing Phase III survodutide results at ADA, we

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

Following recent disappointing Phase III survodutide results at ADA, we

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

Following recent disappointing Phase III survodutide results at ADA, we

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

Following recent disappointing Phase III survodutide results at ADA, we

Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold

Tue, 14 Jul 2026 01:58:23 -0400

Jefferies analyst Lucy Codrington downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Buy to Hold with a price target of DKK320.00 (from DKK505.00).

Following recent disappointing Phase III survodutide results at ADA, we

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Mon, 13 Jul 2026 11:00:00 -0400

Company announcement No. 32 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 28 (July 6 - July 10, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Mon, 13 Jul 2026 11:00:00 -0400

Company announcement No. 32 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Mon, 13 Jul 2026 11:00:00 -0400

Company announcement No. 32 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Mon, 13 Jul 2026 11:00:00 -0400

Company announcement No. 32 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Mon, 06 Jul 2026 11:00:00 -0400

Company announcement No. 31 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 27 (June 29 - July 3, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Mon, 06 Jul 2026 11:00:00 -0400

Company announcement No. 31 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Mon, 06 Jul 2026 11:00:00 -0400

Company announcement No. 31 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Mon, 06 Jul 2026 11:00:00 -0400

Company announcement No. 31 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Tue, 30 Jun 2026 16:01:00 -0400

Company announcement – No. 30 / 2026

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.

In Company Announcement No. 22 / 2026, dated

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Tue, 30 Jun 2026 16:01:00 -0400

Company announcement – No. 30 / 2026

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

In Company Announcement No. 22 / 2026, dated

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Tue, 30 Jun 2026 16:01:00 -0400

Company announcement – No. 30 / 2026

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

In Company Announcement No. 22 / 2026, dated

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Tue, 30 Jun 2026 16:01:00 -0400

Company announcement – No. 30 / 2026

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

In Company Announcement No. 22 / 2026, dated

Capital Group's stake in Zealand Pharma drops below 5%

Tue, 30 Jun 2026 16:00:52 -0400

The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total voting rights in Zealand Pharma A/S (Nasdaq: ZEAL) as of June 26, 2026, according to a company announcement filed June 30, 2026.

The notification was submitted pursuant to Section 38 of the Danish Capital Markets Act. Capital Group noted that neither it nor any of its affiliates own Zealand Pharma shares for their own account. The shares reported in the notification are held by accounts under the discretionary investment management of one or more of Capital Group's investment management companies.

Zealand Pharma is a biotechnology company headquartered in

Capital Group's stake in Zealand Pharma drops below 5%

Tue, 30 Jun 2026 16:00:52 -0400

Zealand Pharma is a biotechnology company headquartered in

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Tue, 30 Jun 2026 16:00:00 -0400

Company announcement No. 29 / 2026

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports receipt on 30 June 2026 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:

As of 26 June 2026, The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Tue, 30 Jun 2026 16:00:00 -0400

Company announcement No. 29 / 2026

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

As of 26 June 2026, The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Tue, 30 Jun 2026 16:00:00 -0400

Company announcement No. 29 / 2026

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

As of 26 June 2026, The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Tue, 30 Jun 2026 16:00:00 -0400

Company announcement No. 29 / 2026

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

As of 26 June 2026, The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

Mon, 29 Jun 2026 11:00:00 -0400

Company announcement No. 28 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

Copenhagen, Denmark, June 29, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 26 (June 22 - June 26, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe